Analysts expect Obalon Therapeutics, Inc. (NASDAQ:OBLN) to report $-0.35 EPS on March, 4.They anticipate $0.25 EPS change or 41.67 % from last quarter’s $-0.6 EPS. After having $-0.35 EPS previously, Obalon Therapeutics, Inc.’s analysts see 0.00 % EPS growth. Obalon Therapeutics, Inc. (NASDAQ:OBLN) has declined 76.71% since February 18, 2018 and is downtrending. Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. – Nasdaq” published on February 17, 2019, Cnbc.com published: “Nasdaq on pace for best month in more than 3 years – CNBC” on January 25, 2019.

Source: Wall Street Journal February 17, 2019 23:26 UTC